COLL Q1 2022 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$84M-4.5% YoY

Gross Profit

$48M57.9% margin

Operating Income

-$10M-12.0% margin

Net Income

-$13M-15.6% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+206.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$1.1B

Stockholders' Equity

$196M

Cash & Equivalents

$107M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$84M	$88M	-4.5%
Gross Profit	$48M	$56M	-12.8%
Operating Income	-$10M	$21M	-147.3%
Net Income	-$13M	$16M	-183.4%

Revenue Segments

Xtampza ER

$32M38%

Nucynta IR

$29M35%

Nucynta ER

$19M23%

Belbuca

$3M4%

Symproic

$300,0000%

Elyxyb

$25,0000%